What does Mepolizumab therapy involve?

Mepolizumab is a biologic therapy administered as a monthly subcutaneous injection. It works by blocking interleukin-5 (IL-5), a protein that drives eosinophil production and activation in eosinophilic severe asthma. The treatment consists of 12 monthly doses given in an outpatient setting, typically requiring 15–30 minutes per visit. It is not a rescue medication but a long-term controller therapy aimed at reducing exacerbations and improving lung function.